1012057-52-1

Basic information

• Product Name: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE
• Synonyms: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE;-7-methoxyquinazoline-4,6-diamine;N4-(3-Ethynylphenyl)
• CAS NO: 1012057-52-1
• Molecular Formula: C₁₇H₁₄N₄O
• Molecular Weight: 290.31926
• Mol File: 1012057-52-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 500.2±50.0 °C(Predicted)
• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6.09±0.30(Predicted)
• CAS DataBase Reference: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE(1012057-52-1)
• EPA Substance Registry System: N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE(1012057-52-1)

Safety Data

• Hazardous Substances Data: 1012057-52-1(Hazardous Substances Data)

Usage

General Description

N4-(3-Ethynylphenyl)-7-methoxyquinazoline-4,6-diamine is a chemical compound with potential biological activities. It belongs to the quinazoline derivative family, and its structure contains an ethynylphenyl group and a methoxy group. N4-(3-ETHYNYLPHENYL)-7-METHOXYQUINAZOLINE-4,6-DIAMINE has shown promising anti-cancer properties in preclinical studies, inhibiting the growth of certain cancer cell lines. It also has potential applications in the development of new drug candidates for the treatment of various diseases, including cancer. Further research is needed to fully understand its mechanism of action and potential therapeutic uses.

Upstream product

• 162012-69-3 7-fluoro-6-nitro-4-hydroxyquinazoline 
• 162012-69-3 7-fluoro-6-nitro-3H-quinazolin-4-one 
• 54060-30-9 3-acetylenephenylamine 
• 55496-69-0 4-chloro-7-methoxy-6-nitroquinazoline 
• 56602-33-6 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
• 207226-02-6 hydrochloric salt of m-aminophenylacetylene 

Downstream Products

• 1430203-46-5 (E)-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide 
• 1203904-22-6 C₂₄H₁₈N₄O₃ 

Relevant articles and documents

Tyrosine kinase inhibitor and pharmaceutical application thereof

The invention relates to a tyrosine kinase inhibitor containing a quinazoline derivative in the fields of tumor treatment medicines and the like, and application of the tyrosine kinase inhibitor in treatment medicines for inhibiting and treating diseases caused by overexpression of tyrosine kinase. The active ingredient of the tyrosine kinase inhibitor is a quinazoline derivative with a structure shown in the following formula: a functional group containing XCH2 (CH2) nC = O is introduced on the basis of a quinazoline structure, and the functional group is easily combined with cysteine sulfydryl through nucleophilic reaction to form a covalent bond so that the activity of tyrosine kinase is irreversibly inhibited.

Synthesis method and related intermediate of N-(3-alkynylphenyl)-4,6-diaminoquinazoline-based compound

The present invention relates to a synthesis method and a related intermediate of a N-(3-alkynylphenyl)-4,6-diaminoquinazoline-based compound.

QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR

The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo,